BioSpace News Archive

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced that a Trial in Progress poster of the ongoing Phase 1/2 clinical trial of seclidemstat in patients with relapsed or refractory Ewing sarcoma will be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:00 p.m. Eastern Time.

Vir Biotechnology, Inc. announced the initiation of a Phase 1 clinical trial of VIR-3434, an investigational monoclonal antibody that neutralizes hepatitis B virus and has been engineered to potentially also act as a therapeutic vaccine.

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., President, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 3:30 p.m. ET.

Coverage Effective Immediately on One of the Largest Payor Networks in the U.S. AMZEEQ ® is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne BRIDGEWATER, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its novel AMZEEQ ® (min

Conventus Orthopaedics, Inc. announced it has completed the acquisition of Flower Orthopedics, the market leader in Ready-for-Surgery™ single use, sterile-packaged, implant and instrument kits.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the completion of its End-of-Pha

Acquist Therapeutics, Inc ., a biopharmaceutical company committed to new treatment for patients with inflammatory diseases, announced the appointment of two new members to its Board of Directors – Thomas P. Haverty , MD, and John R. Redman , MD. “We are honored that these experienced executives are joining our Board of Directors,

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2020 at BIO Digital from June 8-12. For 2020, the BIO International Convention has transitioned to a new, virtual event format. The Company will present its corporate overview for 2020 with a special focus on multiple growth opportunitie

Masimo and Philips Licensing Agreement Brings Masimo NomoLine ® Capnography and O3 ® Regional Oximetry to Select Philips Patient Monitors